ArticleJournal of extracellular vesicles2020
Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.
Article in Journal of extracellular vesicles, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?Paediatric respiratory reviews · 2022Pooled it
- Extracellular Vesicles as Molecular Regulators of Viral Infection: Implications for COVID-19 and Future Viral Pandemics.Current issues in molecular biology · 2026Review
- Naturally occurring ACE2 stalk variants are differentially released from the cell.Scientific reports · 2026Article
- Naturally occurring ACE2 stalk variants are differentially released from the cell.bioRxiv : the preprint server for biology · 2026Article
- Unveiling alternate pathways for SARS-CoV-2 infection via extracellular vesicle-mediated transfer of ACE2 and TMPRSS2.Nature communications · 2026Article
- Nano-Flow Cytometry of Single Extracellular Vesicles Reveals Subpopulation Differences Across Cell Types and Pharmacological Perturbations.Journal of extracellular vesicles · 2026Article
- Microneedle-based delivery of cell membrane vesicles as IL-17RA decoys for Psoriasis treatment.Journal of nanobiotechnology · 2026Article
- Therapeutic Potential of Extracellular Vesicles: From Biogenesis, Isolation and Molecular Characterization to Addressing Translational Gaps and Regulatory Barriers.International journal of molecular sciences · 2026Review
- Extracellular Vesicles Coordinate Bacterial Cloaking in Lung Epithelial Cells to Alleviate Acute Inflammatory Injury.Journal of extracellular vesicles · 2026Article
- ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity.Viruses · 2025Article
- Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron.Cell communication and signaling : CCS · 2025Article
- Engineering Genome-Free Bacterial Cells for Effective SARS-COV-2 Neutralisation.Microbial biotechnology · 2025Article
- The emerging role of extracellular vesicles in viral transmission and immune evasion.Frontiers in immunology · 2025Review
- Circulating extracellular vesicles from severe COVID-19 patients induce lung inflammation.mSphere · 2024Article
- Article
- Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.Expert opinion on drug discovery · 2024Review
- Extracellular vesicles as therapeutics for inflammation and infection.Current opinion in biotechnology · 2024Review
- SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model.iScience · 2024Article
- Lipid Metabolism Modulation during SARS-CoV-2 Infection: A Spotlight on Extracellular Vesicles and Therapeutic Prospects.International journal of molecular sciences · 2024Review
- Exosomes and SARS-CoV-2 infection.Frontiers in immunology · 2024Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by host TMPRSS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2-EVs are efficient decoys for SARS-CoV-2 S protein-containing lentivirus. Reduction of infectivity positively correlates with the level of ACE2, is much more efficient than with soluble ACE2 and further enhanced by the inclusion of TMPRSS2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.